Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience

Omadacycline, a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S. aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC₉₀ 0.25 mg/L), MRSA (MIC₉₀ 0.5 mg/L), S. pneumoniae (MIC₉₀ 0.06 mg/L) and M. catarrhalis (MIC₉₀ 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.